Reports Q3 revenue $10.60M , consensus $18.68M.”Patient starts more than doubled from our second to third quarter update, providing clear evidence that our commercial launches continued to accelerate,” said Andrew Obenshain, chief executive officer. “This momentum, coupled with steps we took in the third quarter to increase manufacturing capacity for ZYNTEGLO and optimize our cost structure, is propelling bluebird forward on our path to becoming a sustainable commercial gene therapy company. We remain focused on securing additional cash resources to extend our runway, which we believe would enable us to achieve this vision and reach cash flow break-even in the second half of 2025.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLUE:
- Bluebird Bio’s Key Decisions and Shareholder Engagement in 2024
- BLUE Earnings this Week: How Will it Perform?
- Largest borrow rate increases among liquid names
- CRISPR Therapeutics Deserves its Lofty Valuation Even with Conservative Forecasts
- Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher